Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OnaBotulinum Toxin A in Resistant Depression
NCT03484754Unknown
- Sponsor
- Centre Hospitalier Esquirol
- Start
- Apr 2018
- Primary completion
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of botulinum toxin type A in major depressive disorder (MDD) (2 arms), sponsored by Centre Hospitalier Esquirol. Primary endpoint: Montgomery-Åsberg Depression Rating Scale Response Rate at 6 weeks. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03484754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03484754.